v3.26.3
DIVISION INFORMATION (SEGMENT REPORTING)
9 Months Ended
Sep. 30, 2026
DIVISION INFORMATION (SEGMENT REPORTING)  
DIVISION INFORMATION (SEGMENT REPORTING)

EDAP TMS S.A. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands of U.S. dollars)

(unaudited)

​

NOTE 17. DIVISION INFORMATION (SEGMENT REPORTING)

Historically, the Company’s activities were organized into three divisions, each of which was a reportable segment: High Intensity Focused Ultrasound (“HIFU”), Lithotripsy (“ESWL”) and Distribution services (“Distribution”). As described in Note 18, on May 28, 2026 the Board of Directors approved a plan to exit the ESWL and Distribution segments to focus the Company exclusively on its HIFU business, and those segments are reported as discontinued operations for all periods presented. Following that classification, HIFU is the Company’s sole continuing reportable segment. The chief operating decision maker, the Company’s Chief Executive Officer, reviews segment operating income or loss for purposes of allocating resources and assessing performance. Segment information for all periods presented below has been recast to reflect the ESWL and Distribution segments as discontinued operations.

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

 

2026

  ​ ​ ​

2025

Operating loss

 

(6,855)

 

(5,818)

​

(22,233)

 

(18,674)

Financial (expense) income, net

 

2,032

 

(56)

​

(5,989)

 

(103)

Foreign currency exchange (losses) gains, net

 

573

 

55

​

625

 

(640)

Income tax (expense) benefit

 

(212)

 

(121)

​

(435)

 

(373)

Consolidated net loss

 

(4,462)

 

(5,940)

​

(28,032)

 

(19,790)

​

A summary of the Company’s operations by segment is presented below for the three and nine months ended September 30, 2026, and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

September 30, 2026

​

Division

​

Items

​

continuing

Sales of goods

 

6,489

​

—

 

6,489

Sales of RPPs & leases

 

2,367

​

—

 

2,367

Sales of spare parts and services

 

972

​

—

 

972

Total sales

 

9,828

​

—

 

9,828

Total cost of sales

 

(4,776)

​

—

 

(4,776)

Gross profit

 

5,053

​

—

 

5,053

R&D expenses

 

(2,458)

​

—

 

(2,458)

Selling and marketing expenses

 

(5,914)

​

—

 

(5,914)

General and administrative expenses

 

(2,823)

 

(1,634)

 

(4,458)

Total expenses

 

(11,195)

 

(1,634)

 

(12,829)

Operating income (loss) from operations

 

(6,142)

 

(1,634)

 

(7,777)

Total Assets

 

44,686

​

48,703

 

93,389

Net cash generated by (used in) investing activities

 

(1,326)

​

—

 

(1,326)

Non-current assets

 

15,933

​

—

 

15,933

Goodwill

 

732

​

—

 

732

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

September 30, 2025

​

Division

​

Items

​

continuing

Sales of goods

 

4,895

 

—

 

4,895

Sales of RPPs & leases

 

2,216

 

—

 

2,216

Sales of spare parts and services

 

717

 

—

 

717

Total sales

 

7,828

 

—

 

7,828

Total cost of sales

 

(4,181)

 

—

 

(4,181)

Gross profit

 

3,647

 

—

 

3,647

R&D expenses

 

(2,303)

 

—

 

(2,303)

Selling and marketing expenses

 

(4,181)

 

—

 

(4,181)

General and administrative expenses

 

(2,575)

 

(1,258)

 

(3,833)

Total expenses

 

(9,059)

 

(1,258)

 

(10,316)

Operating income (loss) from operations

 

(5,412)

 

(1,258)

 

(6,669)

Total Assets

 

48,538

​

5,331

 

53,870

Net cash generated by (used in) investing activities

 

(884)

​

—

 

(884)

Non-current assets

 

14,795

​

—

 

14,795

Goodwill

 

757

​

—

 

757

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine months ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

September 30, 2026

​

Division

​

Items

​

continuing

Sales of goods

 

24,272

​

—

 

24,272

Sales of RPPs & leases

 

7,617

​

—

 

7,617

Sales of spare parts and services

 

2,736

​

—

 

2,736

Total sales

 

34,624

​

—

 

34,624

Total cost of sales

 

(16,271)

​

—

 

(16,271)

Gross profit

 

18,353

​

—

 

18,353

R&D expenses

 

(7,242)

​

—

 

(7,242)

Selling and marketing expenses

 

(19,747)

​

—

 

(19,747)

General and administrative expenses

 

(9,298)

 

(5,899)

 

(15,198)

Total expenses

 

(36,287)

 

(5,899)

 

(42,186)

Operating income (loss) from operations

 

(17,935)

 

(5,899)

 

(23,834)

Total Assets

 

44,686

​

48,703

 

93,389

Net cash generated by (used in) investing activities

 

(3,006)

​

—

 

(3,006)

Non-current assets

 

15,933

​

—

 

15,933

Goodwill

 

732

​

—

 

732

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine months ended

  ​ ​ ​

HIFU

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

September 30, 2025

​

Division

​

Items

​

continuing

Sales of goods

 

15,081

 

—

 

15,081

Sales of RPPs & leases

 

6,315

 

—

 

6,315

Sales of spare parts and services

 

2,441

 

—

 

2,441

Total sales

 

23,838

 

—

 

23,838

Total COS

 

(12,170)

 

—

 

(12,170)

Gross profit

 

11,667

 

—

 

11,667

R&D expenses

 

(6,951)

 

—

 

(6,951)

Selling and marketing expenses

 

(13,874)

 

—

 

(13,874)

G&A expenses

 

(7,359)

 

(3,519)

 

(10,879)

Total expenses

 

(28,185)

 

(3,519)

 

(31,704)

Operating income (loss) from operations

 

(16,517)

 

(3,519)

 

(20,037)

Total Assets

 

48,538

​

5,331

 

53,870

Net cash generated by (used in) investing activities

 

(3,626)

​

—

 

(3,626)

Non-current assets

 

14,795

​

—

 

14,795

Goodwill

 

757

​

—

 

757

​